Esperion Therapeutis.Inc. buy quelbe60
Start price
20.03.23
/
50%
€1.46
Target price
20.03.24
-
Performance (%)
-11.46%
End price
04.04.23
€1.29
Summary
This prediction ended on 04.04.23 with a price of €1.29. The prediction for Esperion Therapeutis.Inc. disappointed with a performance of -11.46%. quelbe60 has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | 4.053% | 4.053% | 59.925% |
| iShares Core DAX® | 0.000% | -2.064% | 13.111% |
| iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% |
| iShares Nikkei 225® | 1.568% | -5.892% | 19.592% |
| iShares S&P 500 | 0.334% | -2.281% | 27.745% |
According to quelbe60 what are the pros and cons of Esperion Therapeutis.Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by quelbe60 for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Buy Esperion Therapeutis.Inc.
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by quelbe60 for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€1.84
14.12.23
14.12.23
-
14.12.24
14.12.24
23.78%
23.12.23
23.12.23
Could be worthwhile Investment >10% per year
